MeOH tetrahydrofuran → HCID 178432026, compound
Reaction equation
C1(S([N:10]2[CH:21]=[CH:20][C:19]3[C:11]2=[N:12][CH:13]=[C:14]2[C:18]=3[N:17]([C:22]3([CH3:37])[CH2:27][CH2:26][N:25]([S:28]([C:31]4[CH:32]=[N:33][CH:34]=[CH:35][CH:36]=4)(=[O:30])=[O:29])[CH2:24][CH2:23]3)[N:16]=[N:15]2)(=O)=O)C=CC=CC=1.C1COCC1.CO>>[CH3:37][C:22]1([N:17]2[C:18]3[C:14](=[CH:13][N:12]=[C:11]4[C:19]=3[CH:20]=[CH:21][NH:10]4)[N:15]=[N:16]2)[CH2:27][CH2:26][N:25]([S:28]([C:31]2[CH:32]=[N:33][CH:34]=[CH:35][CH:36]=2)(=[O:30])=[O:29])[CH2:24][CH2:23]1Participants
Procedure
A mixture of 6-benzenesulfonyl-1-[4-methyl-1-(pyridine-3-sulfonyl)-piperidin-4-yl]-1,6-dihydro-1,2,3,5,6-pentaaza-as-indacene (74.0 mg, 0.14 mmol) in THF/methanol containing aqueous sodium hydroxide (0.53 mmol) was stirred for 64 hr. The solvent was evaporated under vacuum to a small volume, the residue dissolved in DCM, washed with saturated sodium bicarbonate solution and brine, dried over sodium sulfate and concentrated under vacuum and the resulting residue purified by column chromatography on silica gel (gradient: 0 to 5% [2M NH3 in methanol] in DCM) to afford 15.0 mg (27%) of 1-[4-methyl-1-(pyridine-3-sulfonyl)-piperidin-4-yl]-1,6-dihydro-1,2,3,5,6-pentaaza-as-indacene. LCMS (Method A, ESI): RT=3.42 min, m+H=398.2; 1H NMR (400 MHz, DMSO): δ 12.45 (s, 1H), 8.99 (s, 1H), 8.86 (m, 2H), 8.13 (ddd, 1H), 7.65 (m, 2H), 6.91 (dd, 1H), 3.49 (m, 2H), 2.90 (m, 2H), 2.75 (m, 2H), 2.31 (m, 2H), 1.75 (s, 3H).
Workup
- customThe solvent was evaporated under vacuum to a small volume
- dissolutionthe residue dissolved in DCM
- washwashed with saturated sodium bicarbonate solution and brine
- dry with materialdried over sodium sulfate
- concentrationconcentrated under vacuum
- customthe resulting residue purified by column chromatography on silica gel (gradient: 0 to 5% [2M NH3 in methanol] in DCM)
Sources & evidence
- ORD record
- ord-160833e7d5754f6b892a1989ab13cd70
- Source dataset
- uspto-grants-2013_06
- Patent number
- US08461328B2
Reaction notes
Loading…